Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.

[1]  Qing Xiang,et al.  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials , 2006, Molecular Cancer Therapeutics.

[2]  Nader Fotouhi,et al.  Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. , 2006, Journal of medicinal chemistry.

[3]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Pevarello,et al.  Cyclin-dependent kinase inhibitors: a survey of the recent patent literature , 2005 .

[5]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[6]  Peter M Fischer,et al.  Recent progress in the discovery and development of cyclin-dependent kinase inhibitors , 2005, Expert opinion on investigational drugs.

[7]  Hiroshi Hirai,et al.  Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. , 2005, Current topics in medicinal chemistry.

[8]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[9]  E. Sausville,et al.  Homology Model of the CDK1/cyclin B Complex , 2004, Journal of biomolecular structure & dynamics.

[10]  P. Kaldis,et al.  Cdk2 Knockout Mice Are Viable , 2003, Current Biology.

[11]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[12]  P. Fischer,et al.  CDK inhibitors in clinical development for the treatment of cancer , 2003, Expert opinion on investigational drugs.

[13]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[14]  E. Sausville,et al.  Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.

[15]  P. Toogood.  Cyclin‐dependent kinase inhibitors for treating cancer , 2001, Medicinal research reviews.

[16]  S. Mani,et al.  Cyclin-dependent kinase inhibitors: novel anticancer agents , 2000, Expert opinion on investigational drugs.

[17]  Thomas Meyer,et al.  Structure-based design of potent CDK1 inhibitors derived from olomoucine , 2000, J. Comput. Aided Mol. Des..

[18]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[19]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[20]  R. Misra,et al.  Clinical progress of selective cyclin-dependent kinase (CDK) inhibitors , 2006 .

[21]  M. Barbacid,et al.  Driving the cell cycle to cancer. , 2003, Advances in experimental medicine and biology.